Immunogenicity and Safety of Pentavalent Meningococcal MenABCWY Vaccine in Adolescents and Young Adults: Integrated Evidence from Late-Phase Clinical Trials

The pentavalent MenABCWY vaccine combining MenB-fHbp and MenACWY-TT components elicits broad serogroup-specific bactericidal immune responses comparable to licensed MenB-fHbp and MenACWY-CRM vaccines.
Phase 3 non-inferiority trials show MenABCWY’s immunogenicity is consistent across both ACWY-naive and ACWY-primed adolescents and young adults with a favorable and comparable safety profile.
Extended interval and booster studies demonstrate durable immune responses for up to 4 years and support flexible vaccination schedules.
Co-administration with other vaccines and lot-to-lot consistency support operational feasibility for integration into adolescent immunization programs.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

The pentavalent MenABCWY vaccine combining MenB-fHbp and MenACWY-TT components elicits broad serogroup-specific bactericidal immune responses comparable to licensed MenB-fHbp and MenACWY-CRM vaccines.
Phase 3 non-inferiority trials show MenABCWY’s immunogenicity is consistent across both ACWY-naive and ACWY-primed adolescents and young adults with a favorable and comparable safety profile.
Extended interval and booster studies demonstrate durable immune responses for up to 4 years and support flexible vaccination schedules.
Co-administration with other vaccines and lot-to-lot consistency support operational feasibility for integration into adolescent immunization programs.

Sign in free to continue reading